Safety and efficacy of human gingiva-derived mesenchymal stem cells in patients with type 1 diabetes: a double-blind, randomized, placebo-controlled, phase 1 trial
Qi Tang, Li Zhou, Liwen Fan, Wei Zhang, Xixiang Tang, Donglan Zeng, Mei Li, Yanhua Zhu, Mengyin Cai, Jia Yuan, Zheng Chen, Song Guo Zheng · 2026
Read Safety and efficacy of human gingiva-derived mesenchymal stem cells in patients with type 1 diabetes: a double-blind, randomized, placebo-controlled, phase 1 trial by Qi Tang, Li Zhou, Liwen Fan, Wei Zhang, Xixiang Tang, Donglan Zeng, Mei Li, Yanhua Zhu, Mengyin Cai, Jia Yuan, Zheng Chen, Song Guo Zheng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13627707.txt.
Description
Qi Tang and colleagues run the first clinical trial of gum-derived stem cells for type 1 diabetes. Insulin manages the disease but cannot stop the immune attack that kills insulin-making beta cells. Mesenchymal stem cells from human gums calm immunity in many settings. So eighteen patients received four vein infusions of the cells or a placebo, three weeks apart. The trial was double-blind and phase 1, and all patients stayed on routine insulin.
By week twelve the treated group showed better leftover beta cell function and needed less daily insulin, and one patient stopped insulin entirely after the first dose. Blood sugar control matched between groups, and side effects, including low blood sugar, were no worse with the cells. Blood markers hinted the cells tire out attacker T-cells, a lead the authors offer for larger trials.
Catalog record
| CREATOR | Qi Tang, Li Zhou, Liwen Fan, Wei Zhang, Xixiang Tang, Donglan Zeng, Mei Li, Yanhua Zhu, Mengyin Cai, Jia Yuan, Zheng Chen, Song Guo Zheng |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |